Rhophylac

Generic Name: human rho(d) immune globulin
Dosage Form: injection
FULL PRESCRIBING INFORMATION

Rhophylac®
Rh0(D) Immune Globulin Intravenous (Human)

For Intravenous or Intramuscular Injection
Preservative-free, Latex-free, Ready-to-use Prefilled Syringe

Indications and Usage for Rhophylac

1.1 Suppression of Rh Isoimmunization

Pregnancy and Obstetric Conditions

Rhophylac® is indicated for suppression of rhesus (Rh) isoimmunization in non-sensitized Rh0(D)-negative women with an Rh-incompatible pregnancy, including:

• Routine antepartum and postpartum Rh prophylaxis
• Rh prophylaxis in cases of:

  –

  Obstetric complications (e.g., miscarriage, abortion, threatened abortion, ectopic pregnancy or hydatidiform mole, transplacental hemorrhage resulting from antepartum hemorrhage)

  –

  Invasive procedures during pregnancy (e.g., amniocentesis, chorionic biopsy) or obstetric manipulative procedures (e.g., external version, abdominal trauma)

An Rh-incompatible pregnancy is assumed if the fetus/baby is either Rh0(D)-positive or Rh0(D)-unknown or if the father is either Rh0(D)-positive or Rh0(D)-unknown.

Incompatible Transfusions

Rhophylac® is indicated for the suppression of Rh isoimmunization in Rh0(D)-negative individuals transfused with Rh0(D)-positive red blood cells (RBCs) or blood components containing Rh0(D)-positive RBCs.

Treatment can be given without a preceding exchange transfusion when the transfused Rh0(D)-positive blood represents less than 20% of the total circulating RBCs. If the volume exceeds 20%, an exchange transfusion should be considered prior to administering Rhophylac®.

1.2 Immune Thrombocytopenic Purpura (ITP)

 Rhophylac® is indicated in Rh0(D)-positive, non-splenectomized adult patients with chronic ITP to raise platelet counts.

Rhophylac Dosage and Administration

As with all blood products, patients should be observed for at least 20 minutes following administration of Rhophylac®.

2.1 Preparation and Handling

Bring Rhophylac® to room temperature before use.

Rhophylac® is a clear or slightly opalescent, colorless to pale yellow solution. Rhophylac® should be inspected visually for particulate matter and discoloration prior to administration. Do not use if the solution is cloudy or contains particulates. Do not use solution that has been frozen.

Rhophylac® is for single use only. Dispose of any unused product or waste material in accordance with local requirements.

2.2 Suppression of Rh Isoimmunization

Rhophylac® should be administered by intravenous or intramuscular injection. If large doses (greater than 5 mL) are required and intramuscular injection is chosen, it is advisable to administer Rhophylac® in divided doses at different sites.

Table 1 provides dosing guidelines based on the condition being treated.

Table 1: Dosing Guidelines for Suppression of Rh Isoimmunization

Indication	Timing of Administration	Dose* (Administer by Intravenous or Intramuscular Injection)
IU, international units; mcg, micrograms.
* A 1500 IU (300 mcg) dose of Rhophylac®will suppress the immunizing potential of ≥15 mL of Rh0(D)-positive RBCs.1 † The dose of Rhophylac® must be increased if the patient is exposed to >15 mL of Rh0(D)-positive RBCs; in this case, follow the dosing guidelines for excessive fetomaternal hemorrhage.
Rh-incompatible pregnancy
Routine antepartum prophylaxis	At Week 28-30 of gestation	1500 IU (300 mcg)
Postpartum prophylaxis (required only if the newborn is Rh0(D)-positive)	Within 72 hours of birth	1500 IU (300 mcg)†
Obstetric complications (e.g., miscarriage, abortion, threatened abortion, ectopic pregnancy or hydatidiform mole, transplacental hemorrhage resulting from antepartum hemorrhage)	Within 72 hours of complication	1500 IU (300 mcg)†
Invasive procedures during pregnancy (e.g., amniocentesis, chorionic biopsy) or obstetric manipulative procedures (e.g., external version, abdominal trauma)	Within 72 hours of procedure	1500 IU (300 mcg)†
Excessive fetomaternal hemorrhage (>15 mL)	Within 72 hours of complication	1500 IU (300 mcg) plus: 100 IU (20 mcg) per mL fetal RBCs in excess of 15 mL if excess transplacental bleeding is quantified or An additional 1500 IU (300 mcg) dose if excess transplacental bleeding cannot be quantified
Incompatible transfusions	Within 72 hours of exposure	100 IU (20 mcg) per 2 mL transfused blood or per 1 mL erythrocyte concentrate

2.3 ITP

 For treatment of ITP, Rhophylac® must be administered by the intravenous route.

 A 250 IU (50 mcg) per kg body weight dose of Rhophylac® is recommended for patients with ITP. The following formula can be used to calculate the amount of Rhophylac® to administer:

 

 Dose (IU) × body weight (kg) = Total IU / 1500 IU per syringe = # of syringes

 

 Rhophylac® should be administered at a rate of 2 mL per 15 to 60 seconds.

Dosage Forms and Strengths

1500 IU (300 mcg) per 2 mL prefilled syringe

Contraindications

Individuals known to have had an anaphylactic or severe systemic reaction to the administration of human immune globulin products should not receive Rh0(D) immune globulin.

Warnings and Precautions

5.1 Both Indications

Allergic Reactions

Allergic reactions may occur. If symptoms of allergic or early signs of hypersensitivity reactions (including generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis) occur, immediately discontinue administration. The treatment required depends on the nature and severity of the side effect. If necessary, the current medical standards for shock treatment should be observed (see Patient Counseling Information [17.1]).

Selective IgA Deficiency

Individuals with selective IgA deficiency can develop antibodies to IgA and anaphylactic reactions (including anaphylaxis and shock) after administration of blood components containing IgA. Although the concentration of IgA was found to be below the detection limit of 5 mcg/mL, Rhophylac® may contain trace amounts of IgA (see Description [11]).

Those with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. Therefore, the physician must weigh the expected benefits of treatment with Rhophylac® against the potential risks.

Interference With Laboratory Tests

The administration of Rh0(D) immune globulin may affect the results of blood typing, the antibody screening test, and the direct antiglobulin (Coombs') test. Antepartum administration of Rh0(D) immune globulin to the mother can also affect these tests in the newborn infant.

Rhophylac® can contain antibodies to other Rh antigens (e.g., anti-C antibodies), which might be detected by sensitive serological tests following administration.

Transmissible Infectious Agents

Rhophylac® is made from human plasma. Products made from human plasma may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses during manufacturing through solvent/detergent treatment and virus filtration. The solvent/detergent treatment step is effective in inactivating enveloped viruses such as hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The virus filtration step is effective in removing both enveloped and non-enveloped viruses (see Description [11], Patient Counseling Information [17.1]).

Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products. All infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to CSL Behring at 1-800-504-5434. The physician should discuss the risks and benefits of this product with the patient.

5.2 Suppression of Rh Isoimmunization

Postpartum Use Following an Rh-incompatible Pregnancy

Rhophylac® should not be given to the newborn infant (see Pediatric Use [8.4] for pediatric use in incompatible transfusions and in ITP).

5.3 ITP

 Intravascular Hemolysis

 Intravascular hemolysis has occurred in a clinical study with Rhophylac®. All cases resolved completely. However, as reported in the literature, some patients treated with Rh0(D) immune globulin (anti-D) developed clinically compromising anemia, acute renal insufficiency, and, very rarely, disseminated intravascular coagulation (DIC) and death.2

 Following administration of Rhophylac®, patients should be monitored for signs and/or symptoms of intravascular hemolysis and its complications including clinically compromising anemia, acute renal insufficiency, and DIC. Patients experiencing intravascular hemolysis may present with back pain, shaking chills, fever, and, most consistently, hemoglobinuria (see Patient Counseling Information [17.3]).

 ITP patients presenting with signs and/or symptoms of intravascular hemolysis and its complications after Rh0(D) immune globulin administration should have confirmatory laboratory tests. DIC may be difficult to detect in the ITP population; the diagnosis is dependent mainly on laboratory testing.

 If patients who develop hemolysis with clinically compromising anemia after receiving Rhophylac® are to be transfused, Rh0(D)-negative packed RBCs should be used to avoid exacerbating ongoing hemolysis.

 Pre-existing Anemia

 The safety of Rhophylac® in the treatment of ITP has not been established in patients with pre-existing anemia. The physician must weigh the benefits of Rhophylac® against the potential risk of increasing the severity of the anemia.

Adverse Reactions

The most serious adverse reactions in patients receiving Rh0(D) immune globulin have been observed in the treatment of ITP. These reactions include intravascular hemolysis, clinically compromising anemia, acute renal insufficiency, and, very rarely, DIC and death (see Warnings and Precautions [5.3]).

The most common adverse reactions observed in the use of Rhophylac® for suppression of Rh isoimmunization are nausea, dizziness, headache, injection-site pain, and malaise.

The most common adverse reactions observed in the treatment of ITP are chills, pyrexia/increased body temperature, and headache. Mild extravascular hemolysis (manifested by an increase in bilirubin and a decrease in hemoglobin) was also observed.

6.1 Clinical Studies Experience

Because clinical studies are conducted under different protocols and widely varying conditions, adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in practice.

Suppression of Rh Isoimmunization

In two clinical studies, 447 Rh0(D)-negative pregnant women received either an intravenous or intramuscular injection of Rhophylac® 1500 IU (300 mcg) at Week 28 of gestation. A second 1500 IU (300 mcg) dose was administered to 267 (9 in Study 1 and 258 in Study 2) of these women within 72 hours of the birth of an Rh0(D)-positive baby. In addition, 30 women in Study 2 received at least one extra antepartum 1500 IU (300 mcg) dose due to obstetric complications (see Clinical Studies [14.1]).

The most common adverse reactions were nausea (0.7%), dizziness (0.5%), headache (0.5%), injection-site pain (0.5%), and malaise (0.5%). A laboratory finding of a transient positive anti-C antibody test was observed in 0.9% of subjects. All adverse reactions were mild to moderate in intensity.

ITP

In a clinical study, 98 Rh0(D)-positive adult subjects with chronic ITP received an intravenous dose of Rhophylac® 250 IU (50 mcg) per kg body weight (see Clinical Studies [14.2]). Premedication to alleviate infusion-related side effects was not used except in a single subject who received acetaminophen and diphenhydramine.

Adverse reactions were mild to moderate in intensity with the exception of one case of severe headache. Eighty-four (85.7%) subjects experienced 392 treatment-emergent adverse events (TEAEs). Sixty-nine (70.4%) subjects had 186 drug-related TEAEs (defined as TEAEs with a probable, possible, definite, or unknown relationship to the study drug). Within 24 hours of dosing, 73 (74.5%) subjects experienced 183 TEAEs, and 66 (67%) subjects experienced 156 drug-related TEAEs.

Mild extravascular hemolysis, manifested as an increase in bilirubin, a decrease in hemoglobin, or a decrease in haptoglobin, was observed, as expected when an anti-D product is given to an Rh-positive individual. An increase in blood bilirubin was seen in 21% of subjects. The median decrease in hemoglobin was greatest (0.8 g/dL) at Day 6 and Day 8 following administration of Rhophylac®.

Table 2 shows the most common TEAEs observed in the clinical study.

Table 2: Most Common Treatment-Emergent Adverse Events (TEAEs) in Subjects With ITP

TEAE	Number of Subjects (%) With a TEAE n=98	Number of Subjects (%) With a Drug-Related TEAE* n=98
* Defined as TEAEs with a possible, probable, definite, or unknown relationship to the study drug.
Chills	34 (34.7%)	34 (34.7%)
Pyrexia/ Increased body temperature	32 (32.6%)	30 (30.6%)
Increased blood bilirubin	21 (21.4%)	21 (21.4%)
Headache	14 (14.3%)	11 (11.2%)

Serious adverse events (SAEs) were reported in 10 (10.2%) subjects. SAEs considered to be drug-related were intravascular hemolytic reaction (hypotension, nausea, chills and headache, and a decrease in haptoglobin and hemoglobin) in two subjects; headache, dizziness, nausea, pallor, shivering, and weakness requiring hospitalization in one subject; and an increase in blood pressure and severe headache in one subject. All four subjects recovered completely.

6.2 Postmarketing Experience

Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure. Evaluation and interpretation of these postmarketing reactions is confounded by underlying diagnosis, concomitant medications, pre-existing conditions, and inherent limitations of passive surveillance.

Suppression of Rh Isoimmunization

The following adverse reactions have been identified during postapproval use of Rhophylac® for suppression of Rh isoimmunization: hypersensitivity reactions, including rare cases of anaphylactic shock or anaphylactoid reactions, headache, dizziness, vertigo, hypotension, tachycardia, dyspnea, nausea, vomiting, rash, erythema, pruritus, chills, pyrexia, malaise, and, rarely, diarrhea and back pain. Transient injection-site irritation and pain have been observed following intramuscular administration.

ITP

Transient hemoglobinuria has been reported in a patient being treated with Rhophylac® for ITP.

Drug Interactions

7.1 Live Virus Vaccines

Immunoglobulin administration may transiently impair the efficacy of live attenuated virus vaccines such as measles, mumps, rubella, and varicella. The immunizing physician should be informed of recent therapy with Rhophylac® so that appropriate measures can be taken (see Patient Counseling Information [17.1]).

USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C. Animal reproduction studies have not been conducted with Rhophylac®.

Suppression of Rh Isoimmunization

The available evidence suggests that Rhophylac® does not harm the fetus or affect future pregnancies or reproduction capacity when given to pregnant Rh0(D)-negative women for suppression of Rh isoimmunization.

ITP

Rhophylac® has not been evaluated in pregnant women with ITP.

8.3 Nursing Mothers

Suppression of Rh Isoimmunization

Rhophylac® is used in nursing mothers for the suppression of Rh isoimmunization. No undesirable effects on a nursing infant are expected during breastfeeding.

ITP

Rhophylac® has not been evaluated in nursing mothers with ITP.

8.4 Pediatric Use

Suppression of Rh Isoimmunization in Incompatible Transfusions

The safety and effectiveness of Rhophylac® have not been established in pediatric subjects being treated for an incompatible transfusion. The physician should weigh the potential risks against the benefits of Rhophylac®, particularly in girls whose later pregnancies may be affected if Rh isoimmunization occurs.

ITP

Studies have demonstrated the safe and effective use of Rh0(D) Immune Globulin in children with ITP.3-6

8.5 Geriatric Use

Suppression of Rh Isoimmunization in Incompatible Transfusions

Rhophylac® has not been evaluated for treating incompatible transfusions in subjects 65 years of age and older.

ITP

Of the 98 subjects evaluated in the clinical study of Rhophylac® for treatment of ITP (see Clinical Studies [14.2]), 19% were 65 years of age and older. No overall differences in effectiveness or safety were observed between these subjects and younger subjects.

Overdosage

There are no reports of known overdoses in patients being treated for suppression of Rh isoimmunization or ITP. Patients with incompatible transfusion or ITP who receive an overdose of Rh0(D) immune globulin should be monitored because of the risk of hemolysis.

Rhophylac Description

Rhophylac® is a sterile Rh0(D) Immune Globulin Intravenous (Human) solution in a ready-to-use prefilled syringe for intravenous or intramuscular injection. One syringe contains at least 1500 IU (300 mcg) of IgG antibodies to Rh0(D) in a 2 mL solution, sufficient to suppress the immune response to at least 15 mL of Rh-positive RBCs.1 The product potency is expressed in IUs by comparison to the World Health Organization (WHO) standard, which is also the US and the European Pharmacopoeia standard.

Plasma is obtained from healthy Rh0(D)-negative donors who have been immunized with Rh0(D)-positive RBCs. The donors are screened carefully to reduce the risk of receiving donations containing blood-borne pathogens. Each plasma donation used in the manufacture of Rhophylac® is tested for the presence of HBV surface antigen (HBsAg), HIV-1/2, and HCV antibodies. In addition, plasma used in the manufacture of Rhophylac® is tested by FDA-licensed Nucleic Acid Testing (NAT) for HIV and HCV and found to be negative. An investigational NAT for HBV is also performed on all source plasma used and found to be negative; however, the significance of a negative result has not been established. The source plasma is also tested by NAT for hepatitis A virus (HAV) and B19 virus (B19V).

Rhophylac® is produced by an ion-exchange chromatography isolation procedure7, using pooled plasma obtained by plasmapheresis of immunized Rh0(D)-negative US donors. The manufacturing process includes a solvent/detergent treatment step (using tri-n-butyl phosphate and Triton™ X-100) that is effective in inactivating enveloped viruses such as HIV, HCV, and HBV.8,9 Rhophylac® is filtered using a Planova® 15 nanometer (nm) virus filter that has been validated to be effective in removing both enveloped and non-enveloped viruses. Table 3 presents viral clearance and inactivation data from validation studies, expressed as the mean log10 reduction factor.

Table 3: Virus Inactivation and Removal in Rhophylac®

Virus	HIV	PRV	BVDV	MVM
HIV, a model for HIV-1 and HIV-2; PRV, pseudorabies virus, a model for large, enveloped DNA viruses (e.g., herpes virus); BVDV, bovine viral diarrhea virus, a model for HCV; MVM, minute virus of mice, a model for B19V and other small, non-enveloped DNA viruses.
Genome	RNA	DNA	RNA	DNA
Envelope	Yes	Yes	Yes	No
Size	80-100 nm	120-200 nm	40-70 nm	18-24 nm
Solvent/detergent treatment	≥6.0	≥5.6	≥5.4	Not tested
Chromatographic process steps	4.5	≥3.9	1.6	≥2.6
Virus filtration	≥6.3	≥5.6	≥5.5	3.4
Overall reduction (log10 units)	≥16.8	≥15.1	≥12.5	≥6.0

Rhophylac® contains a maximum of 30 mg/mL of human plasma proteins, 10 mg/mL of which is human albumin added as a stabilizer. Prior to the addition of the stabilizer, Rhophylac® has a purity greater than 95% IgG. Rhophylac® contains less than 5 mcg/mL of IgA, which is the limit of detection. Additional excipients are approximately 20 mg/mL of glycine and up to 0.25 M of sodium chloride. Rhophylac® contains no preservative. Human albumin is manufactured from pooled plasma of US donors by cold ethanol fractionation, followed by pasteurization.

Rhophylac - Clinical Pharmacology

12.1 Mechanism of Action

Suppression of Rh Isoimmunization

The mechanism by which Rh0(D) immune globulin suppresses immunization to Rh0(D)-positive RBCs is not completely known.

In a clinical study of Rh0(D)-negative healthy male volunteers, both the intravenous and intramuscular administration of a 1500 IU (300 mcg) dose of Rhophylac® 24 hours after injection of 15 mL of Rh0(D)-positive RBCs resulted in an effective clearance of Rh0(D)-positive RBCs. On average, 99% of injected RBCs were cleared within 12 hours following intravenous administration and within 144 hours following intramuscular administration.

ITP

Rhophylac® has been shown to increase platelet counts and to reduce bleeding in non-splenectomized Rh0(D)-positive subjects with chronic ITP. The mechanism of action is thought to involve the formation of Rh0(D) immune globulin RBC complexes, which are preferentially removed by the reticuloendothelial system, particularly the spleen. This results in Fc receptor blockade, thus sparing antibody-coated platelets.10

12.3 Pharmacokinetics

Suppression of Rh Isoimmunization

In a clinical study comparing the pharmacokinetics of intravenous versus intramuscular administration, 15 Rh0(D)-negative pregnant women received a single 1500 IU (300 mcg) dose of Rhophylac® at Week 28 of gestation.11

Following intravenous administration, peak serum levels of Rh0(D) immune globulin ranged from 62 to 84 ng/mL after 1 day (i.e., the time the first blood sample was taken following the antepartum dose). Mean systemic clearance was 0.20 ± 0.03 mL/min, and half-life was 16 ± 4 days.

Following intramuscular administration, peak serum levels ranged from 7 to 46 ng/mL and were achieved between 2 and 7 days. Mean apparent clearance was 0.29 ± 0.12 mL/min, and half-life was 18 ± 5 days. The absolute bioavailability of Rhophylac® was 69%.

Regardless of the route of administration, Rh0(D) immune globulin titers were detected in all women up to at least 9 weeks following administration of Rhophylac®.

ITP

Pharmacokinetic studies with Rhophylac® were not performed in Rh0(D)-positive subjects with ITP. Rh0(D) immune globulin binds rapidly to Rh0(D)-positive erythrocytes.12

Clinical Studies

14.1 Suppression of Rh Isoimmunization

In two clinical studies, 447 Rh0(D)-negative pregnant women received a 1500 IU (300 mcg) dose of Rhophylac® during Week 28 of gestation. The women who gave birth to an Rh0(D)-positive baby received a second 1500 IU (300 mcg) dose within 72 hours of birth.

• Study 1 – Eight of the women who participated in the pharmacokinetic study (see Clinical Pharmacology [12.3]) gave birth to an Rh0(D)-positive baby and received the postpartum dose of 1500 IU (300 mcg) of Rhophylac®.11 Antibody tests performed 6 to 8 months later were negative for all women. This suggests that no Rh0(D) immunization occurred.
• Study 2 – In an open-label, single-arm clinical study at 22 centers in the US and United Kingdom, 432 pregnant women received the antepartum dose of 1500 IU (300 mcg) of Rhophylac® either as an intravenous or intramuscular injection (two randomized groups of 216 women each).13 Subjects received an additional 1500 IU (300 mcg) dose if an obstetric complication occurred between the routine antepartum dose and birth or if extensive fetomaternal hemorrhage was measured after birth. Of the 270 women who gave birth to an Rh0(D)-positive baby, 248 women were evaluated for Rh0(D) immunization 6 to 11.5 months postpartum. None of these women developed antibodies against the Rh0(D) antigen.

14.2 ITP

In an open-label, single-arm, multicenter study, 98 Rh0(D)-positive adult subjects with chronic ITP and a platelet count of 30 × 109/L or less were treated with Rhophylac®. Subjects received a single intravenous dose of 250 IU (50 mcg) per kg body weight.

The primary efficacy endpoint was the response rate defined as achieving a platelet count of ≥30 × 109/L as well as an increase of >20 × 109/L within 15 days after treatment with Rhophylac®. Secondary efficacy endpoints included the response rate defined as an increase in platelet counts to ≥50 × 109/L within 15 days after treatment and, in subjects who had bleeding at baseline, the regression of hemorrhage defined as any decrease from baseline in the severity of overall bleeding status.

Table 4 presents the primary response rates for the intent-to-treat (ITT) and per-protocol (PP) populations.

Table 4: Primary Response Rates (ITT and PP Populations)

Analysis Population	No. Subjects	No. Responders	Primary Response Rate at Day 15
			% Responders	95% Confidence Interval (CI)
ITT	98	65	66.3%	56.5%, 74.9%
PP	92	62	67.4%	57.3%, 76.1%

The primary efficacy response rate (ITT population) demonstrated a clinically relevant response to treatment, i.e., the lower bound of the 95% CI was greater than the predefined response rate of 50%. The median time to platelet response was 3 days, and the median duration of platelet response was 22 days.

Table 5 presents the response rates by baseline platelet count for subjects in the ITT population.

Table 5: Response Rates By Baseline Platelet Count (ITT Population)

		Response Rates at Day 15
Baseline Platelet count (× 109/L)	Total No. Subjects	No. (%) Subjects Achieving a Platelet Count of ≥30 × 109/L and an Increase of >20 × 109/L	No. (%) Subjects With an Increase in Platelet Counts to ≥50 × 109/L
* Reflects subjects with a platelet count of ≤30 × 109/L at screening but >30 × 109/L immediately before treatment.
≤10	38	15 (39.5)	10 (26.3)
>10 to 20	28	22 (78.6)	17 (60.7)
>20 to 30	27	24 (88.9)	22 (81.5)
>30*	5	4 (80.0)	5 (100.0)
Overall (all subjects)	98	65 (66.3)	54 (55.1)

During the study, an overall regression of hemorrhage was seen in 44 (88%, 95% CI: 76% to 94%) of the 50 subjects with bleeding at baseline. The percentage of subjects showing a regression of hemorrhage increased from 20% at Day 2 to 64% at Day 15. There was no evidence of an association between the overall hemorrhage regression rate and baseline platelet count.

Approximately half of the 98 subjects in the ITT population had evidence of bleeding at baseline. Post-baseline, the percentage of subjects without bleeding increased to a maximum of 70.4% at Day 8.

REFERENCES

1. Pollack W, Ascari WQ, Kochesky RJ, O'Connor RR, Ho TY, Tripodi D. Studies on Rh prophylaxis. 1. relationship between doses of anti-Rh and size of antigenic stimulus. Transfusion. 1971;11:333-339.
2. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh0(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood. 2005;106:1532-1537.
3. Tarantino MD, Young G, Bertolone SJ, et al; Acute ITP Study Group. Single dose of anti-D immune globulin at 75 µg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr. 2006;148:489-94.
4. Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997 15;89:2689-2700.
5. Andrew M, Blanchette VS, Adams M, et al. A multicenter study of the treatment of childhood chronic idiopathic thrombocytopenic purpura with anti-D. J Pediatr. 1992;120:522-527.
6. Blanchette V, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet. 1994;344:703-707.
7. Stucki M, Moudry R, Kempf C, Omar A, Schlegel A, Lerch PG. Characterisation of a chromatographically produced anti-D immunoglobulin product. J Chromatogr B. 1997;700:241-248.
8. Horowitz B, Chin S, Prince AM, Brotman B, Pascual D, Williams B. Preparation and characterization of S/D-FFP, a virus sterilized "fresh frozen plasma". J Thromb Haemost. 1991;65:1163.
9. Horowitz B, Bonomo R, Prince AM, Chin S, Brotman B, Shulman RW. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood. 1992;79:826-831.
10. Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci. 2003;28:249-255.
11. Bichler J, Schöndorfer G, Pabst G, Andresen I. Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. BJOG. 2003;110:39-45.
12. Ware RE, Zimmerman SA. Anti-D: mechanisms of action. Semin Hematol. 1998;35:14-22.
13. MacKenzie IZ, Bichler J, Mason GC, et al. Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulin. Eur J Obstetr Gynecol Reprod Biol. 2004;117:154-161.

How Supplied/Storage and Handling

Rhophylac® 1500 IU (300 mcg) is supplied in packages of one or 10 latex-free, ready-to-use, prefilled syringes, each containing 2 mL of preservative-free liquid. Each syringe is accompanied by a SafetyGlide™ needle for intravenous or intramuscular use.

NDC Number	Product Description
44206-300-01	1 prefilled 2 mL syringe
44206-300-10	10 prefilled 2 mL syringes

Store at 2–8°C (36–46°F). If stored at this temperature, Rhophylac® has a shelf life of 36 months from the date of manufacture, as indicated by the expiration date printed on the outer carton and syringe label. Do not freeze. Keep Rhophylac® in its original carton to protect it from light.

Patient Counseling Information

17.1 Both Indications

Allergic Reactions

Inform patients of the early signs of allergic or hypersensitivity reactions to Rhophylac® including hives, chest tightness, wheezing, hypotension, and anaphylaxis (see Warnings and Precautions [5.1]) and advise them to notify their physician if they experience any of these symptoms.

Transmissible Infectious Agents

Inform patients that Rhophylac® is made from human plasma (part of the blood) and may contain infectious agents that can cause disease (e.g., viruses and, theoretically, the CJD agent). Explain that the risk that Rhophylac® may transmit an infectious agent has been reduced by screening the plasma donors, by testing the donated plasma for certain virus infections, and by inactivating and/or removing certain viruses during manufacturing (see Warnings and Precautions [5.1]).

Live Virus Vaccines

Inform patients that administration of immunoglobulin may temporarily impair the effectiveness of live virus vaccines (e.g., measles, mumps, rubella, and varicella) and to notify their immunizing physician of recent therapy with Rhophylac® (see Drug Interactions [7.1]).

17.2 Suppression of Rh Isoimmunization

Standard Dosing for Rh Isoimmunization

Inform patients receiving the antepartum dose of Rhophylac® for suppression of Rh isoimmunization that they will need a second dose within 72 hours of birth if the baby's blood type is Rh-positive (see Dosage and Administration for Suppression of Rh Isoimmunization [2.2]).

17.3 ITP

Intravascular Hemolysis

Instruct patients being treated with Rhophylac® for ITP to immediately report symptoms of intravascular hemolysis, including back pain, shaking chills, fever, discolored urine, decreased urine output, sudden weight gain, edema, and/or shortness of breath (see Warnings and Precautions [5.3]).

Manufactured by:
CSL Behring AG
Bern, Switzerland
US License No. 1766

Distributed by:
CSL Behring LLC
Kankakee, IL 60901 USA

Triton™ is a trademark of The Dow Chemical Company
Planova® is a registered trademark of Asahi Kasei Medical Co., Ltd.
SafetyGlide™ is a trademark of Becton, Dickinson and Company

Part Number: OBMK G46 01528 (19841A) 0443

Package Label - Principal Display Panel - Single Carton

NDC 44206-300-01

300 mcg

Rhophylac®

Rh0(D) Immune Globulin Intravenous (Human)

1500 IU

For Intravenous or Intramuscular Injection. Rx only

CSL Behring

Package Label - Principal Display Panel - Bulk Carton

NDC 44206-300-10

300 mcg

Rhophylac®
Rh0(D) Immune Globulin
Intravenous (Human)
1500 IU

For Intravenous or Intramuscular Injection.

Rx only

CSL Behring

Rhophylac  human rho(d) immune globulin  solution

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 44206-300 Route of Administration INTRAVENOUS, INTRAMUSCULAR DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength HUMAN RHO(D) IMMUNE GLOBULIN (HUMAN RHO(D) IMMUNE GLOBULIN) HUMAN RHO(D) IMMUNE GLOBULIN 1500 [iU]  in 2 mL

Inactive Ingredients Ingredient Name Strength Albumin Human 10 mg  in 1 mL Human Immunoglobulin A   Glycine   Sodium Chloride

Product Characteristics Color      Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 44206-300-01 1 SYRINGE In 1 CARTON contains a SYRINGE, GLASS 1 2 mL In 1 SYRINGE, GLASS This package is contained within the CARTON (44206-300-01) 2 44206-300-10 10 SYRINGE In 1 CARTON contains a SYRINGE, GLASS 2 2 mL In 1 SYRINGE, GLASS This package is contained within the CARTON (44206-300-10)

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
BLA	BLA125070	01/06/2009

Labeler - CSL Behring AG (481152762)

Establishment
Name	Address	ID/FEI	Operations
CSL Behring LLC		931896963	MANUFACTURE

Revised: 01/2009CSL Behring AG